Bruce A. Larson

Bruce A. Larson

Auto-generated profile, based on publicly available information

Bruce A. Larson

Global Health, Boston University School of Public Health, Boston, MA, 02118, USA

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2014 in Bulletin of the World Health Organization
Verified
Journal Article
Open access
EMElliot Marseille
Elliot Marseille
BLBruce Larson
Bruce Larson
DKDhruv S Kazi
Dhruv S Kazi
JKJames G Kahn
James G Kahn
SRSydney Rosen
Sydney Rosen
Many countries use the cost-effectiveness thresholds recommended by the World Health Organization's Choosing Interventions that are Cost-Effective project (WHO-CHOICE) when evaluating health interventions. This project sets the threshold for cost-effectiveness as the cost of the intervention per disability-adjusted life-year (DALY) averted less than three times the country's annual gross domestic product (GDP) per capita. Highly cost-effective interventions are defined as meeting a threshold per DALY averted of once the annual GDP per capita. We argue that reliance on these thresholds reduces the value of cost-effectiveness analyses and makes such analyses too blunt to be useful for most decision-making in the field of public health. Use of these thresholds has little theoretical justification, skirts the difficult but necessary ranking of the relative values of locally-applicable interventions and omits any consideration of what is truly affordable. The WHO-CHOICE thresholds set such a low bar for cost-effectiveness that very few interventions with evidence of efficacy can be ruled out. The thresholds have little value in assessing the trade-offs that decision-makers must confront. We present alternative approaches for applying cost-effectiveness criteria to choices in the allocation of health-care resources.

1 October 1990 in Journal of Development Economics
Verified
Journal Article
Closed access
BLBruce A. Larson
Bruce A. Larson
DBDaniel W. Bromley
Daniel W. Bromley

29 April 2010 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
BLBruce A. Larson
Bruce A. Larson
ABAlana Brennan
Alana Brennan
LMLynne McNamara
Lynne McNamara
LLLawrence Long
Lawrence Long
SRSydney Rosen
Sydney Rosen
MFMatthew P. Fox
Matthew P. Fox
Summary: Objective  To estimate loss to follow up (LTFU) between initial enrolment and the first scheduled return medical visit of a pre‐antiretroviral therapy (ART) care program for patients not eligible for ART.Methods  The study was conducted at a public‐sector HIV clinic in Johannesburg. We reviewed records of all patients newly enrolled in the pre‐ART care program and not yet eligible for ART between January 2007 and February 2008. Crude proportions of patients completing their first return medical visit stratified by patient characteristics were calculated. A modified‐Poisson approach was used to estimate directly relative risks of returning for their first return medical visit within 1 year adjusting for patient characteristics as potential confounders.Results  A total of 356 patients were identified. Two‐thirds had a CD4 count > 350 cells/μl (median [IQR] CD4 = 458 [394, 585]) and were scheduled to return in 6 months for a first medical visit. Seventy‐four percent of these patients did not return within one year for this visit. The remaining 36% of all patients had a baseline CD4 count 251–350 cells/μl and were scheduled to return in 3 months. Only 6% of these patients returned within 4 months; 41% returned within one year. Relative risks were positively associated with a patient being employed and negatively associated with the baseline CD4 count.Conclusions  Given the high rate of LTFU immediately after enroling in pre‐ART care, it is clear that care programs are not expediting the timely initiation of ART. Significantly improved adherence to pre‐ART care and monitoring for patients not yet eligible for ART is required for South Africa to achieve its AIDS strategy goals and reduce the problem of late presentation and initiation of ART.

3 February 2013 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
KCKate Clouse
Kate Clouse
APAudrey Pettifor
Audrey Pettifor
KSKate Shearer
Kate Shearer
MMMHAIRI MASKEW
MHAIRI MASKEW
JBJean Bassett
Jean Bassett
MFMatthew P. Fox
Matthew P. Fox
Objective: HIV‐positive pregnant women are at heightened risk of becoming lost to follow‐up (LTFU) from HIV care. We examined LTFU before and after delivery among pregnant women newly diagnosed with HIV.Methods: Observational cohort study of all pregnant women ≥18 years (N = 300) testing HIV positive for the first time at their first ANC visit between January and June 2010, at a primary healthcare clinic in Johannesburg, South Africa. Women (n = 27) whose delivery date could not be determined were excluded.Results: Median (IQR) gestation at HIV testing was 26 weeks (21–30). Ninety‐eight per cent received AZT prophylaxis, usually started at the first ANC visit. Of 139 (51.3%) patients who were ART eligible, 66.9% (95% CI 58.8–74.3%) initiated ART prior to delivery; median (IQR) ART duration pre‐delivery was 9.5 weeks (5.1–14.2). Among ART‐eligible patients, 40.5% (32.3–49.0%) were cumulatively retained through 6 months on ART. Of those ART‐ineligible patients at HIV testing, only 22.6% (95% CI 15.9–30.6%) completed CD4 staging and returned for a repeat CD4 test after delivery. LTFU (≥1 month late for last scheduled visit) before delivery was 20.5% (95% CI 16.0–25.6%) and, among those still in care, 47.9% (95% CI 41.2–54.6%) within 6 months after delivery. Overall, 57.5% (95% CI 51.6–63.3%) were lost between HIV testing and 6 months post‐delivery.Conclusions: Our findings highlight the challenge of continuity of care among HIV‐positive pregnant women attending antenatal services, particularly those ineligible for ART.

1 October 2012 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
BLBruce A. Larson
Bruce A. Larson
KSKathryn Mpa Schnippel
Kathryn Mpa Schnippel
BNBuyiswa Ba Ndibongo
Buyiswa Ba Ndibongo
TXThembisile MBChB Xulu
Thembisile MBChB Xulu
ABAlana Brennan
Alana Brennan
SRSydney Mpa Rosen
Sydney Mpa Rosen
Background: A mobile HIV counseling and testing (HCT) program around Johannesburg piloted the integration of point-of-care (POC) CD4 testing, using the Pima analyzer, to improve linkages to HIV care. We report results from this pilot program for patients testing positive (n = 508) from May to October 2010. Methods: We analyzed 3 primary outcomes: assignment to testing group (offered POC CD4 or not), successful follow-up (by telephone), and completed the referral visit for HIV care within 8 weeks after HIV testing if successfully followed up. Proportions for each outcome were calculated, and relative risks were estimated using a modified Poisson approach. Results: Three hundred eleven patients were offered the POC CD4 test, and 197 patients were not offered the test. No differences in patient characteristics were observed between the 2 groups. Approximately 62.7% of patients were successfully followed up 8 weeks after HIV testing, with no differences observed between testing groups. Among those followed up, 54.4% reported completing their referral visit. Patients offered the POC CD4 test were more likely to complete the referral visit for further HIV care (relative risk 1.25, 95% confidence interval: 1.00 to 1.57). Conclusions: In this mobile HCT setting, patients offered POC CD4 testing as part of the HCT services were more likely to visit a referral clinic after testing, suggesting that rapid CD4 testing technology may improve linkage to HIV care. Future research can evaluate options for adjusting HCT services if POC CD4 testing was included permanently and the cost-effectiveness of the POC CD4 testing compared with other approaches for improving linkage of care.

16 April 2010 in Bulletin of the World Health Organization
Verified
Journal Article
Closed access
BLBruce A Larson
Bruce A Larson
ABAlana Brennan
Alana Brennan
LMLynne McNamara
Lynne McNamara
LLLawrence Long
Lawrence Long
SRSydney Rosen
Sydney Rosen
MFMatthew P Fox
Matthew P Fox
To estimate rates of completion of CD4+ lymphocyte testing (CD4 testing) within 12 weeks of testing positive for human immunodeficiency virus (HIV) at a large HIV/AIDS clinic in South Africa, and to identify clinical and demographic predictors for completion. In our study, CD4 testing was considered complete once a patient had retrieved the test results. To determine the rate of CD4 testing completion, we reviewed the records of all clinic patients who tested positive for HIV between January 2008 and February 2009. We identified predictors for completion through multivariate logistic regression. Of the 416 patients who tested positive for HIV, 84.6% initiated CD4 testing within the study timeframe. Of these patients, 54.3% were immediately eligible for antiretroviral therapy (ART) because of a CD4 cell count ≤ 200/µl, but only 51.3% of the patients in this category completed CD4 testing within 12 weeks of HIV testing. Among those not immediately eligible for ART (CD4 cells > 200/µl), only 14.9% completed CD4 testing within 12 weeks. Overall, of HIV+ patients who initiated CD4 testing, 65% did not complete it within 12 weeks of diagnosis. The higher the baseline CD4 cell count, the lower the odds of completing CD4 testing within 12 weeks. Patient losses between HIV testing, baseline CD4 cell count and the start of care and ART are high. As a result, many patients receive ART too late. Health information systems that link testing programmes with care and treatment programmes are needed.